BENGALURU (Reuters) – India’s Ind-Swift Laboratories said on Wednesday it would sell its active pharmaceuticals ingredients (API) and contract research and manufacturing services (CRAMS) business to Synthimed Labs in a deal with an enterprise value of 16.50 billion rupees ($198.50 million). ($1 = 83.1238 Indian rupees)
(Reporting by Ashish Chandra in Bengaluru; Editing by Savio D’Souza)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.